Going beyond anti-PD1 checkpoint blockade is important if we want to help more people respond to cancer immunotherapy
FDA slaps a partial clinical hold for unwanted side effects, now what?
There are a number of important lessons we can learn from early phase 1 trials. Here are some of them.
What is old is new again - a look at some forgotten oncology targets that are coming back in fashion
Update on PIVOT-02 with nivolumab plus NKTR-214 in 1L metastatic melanoma
The evolving story of how commensal microbiota can affect response to cancer immunotherapy
Latest news and insights on immune escape mechanisms associated with cancer immunotherapy
An extensive round-up of what to expect from SITC18 ahead of the abstract reveal
